1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Health and Happiness (H&H) International Holdings Limited

Health and Happiness (H&H) International Holdings Limited

2.02
EUR
-0.04
(-1.94%)
768.22MMarket Cap
Mar 23Next Earn
Health and Happiness (H&H) International Holdings Limited
MUN:8BI
(Munich Stock Exchange)

Recent

price

2.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.7
3.63
5.62
7.57
7.86
7.85
10.32
12.78
15.89
17.04
17.39
17.91
19.96
21.76
20.35
22.37
- -
Revenue per Share
0.58
0.88
1.23
1.36
1.34
0.41
1.51
1.47
1.32
1.57
1.77
0.79
0.96
0.91
-0.08
0.31
- -
Basic EPS, GAAP
0.8
0.76
1.5
0.87
1.37
0.41
2.31
2.16
2.25
2.04
2.21
2.77
2.14
1.57
1.95
2.25
- -
Free Cash Flow per Basic Share
0.32
0.3
0.67
1.03
0.82
0.32
- -
- -
- -
0.42
1.34
0.63
0.37
0.74
0.44
0.22
- -
Dividend per Share
2.77
3.28
3.86
4.18
4.81
5.23
5.01
6.61
7.57
8.7
9.63
9.12
9.51
9.75
9.01
9.28
10.09
Book Value per Share
2.76
3.28
3.82
3.76
4.41
-7.3
-8.26
-7.52
-6.39
-5.42
-6.25
-11.1
-11.2
-11.03
-10.98
-10.39
-9.18
Tangible Book Value per Share
456
602
602
602
602
614
630
634
638
641
644
645
640
640
641
642
644
Basic Weighted Avg Shares
1,234
2,189
3,382
4,561
4,732
4,819
6,506
8,095
10,132
10,925
11,195
11,548
12,776
13,926
13,052
14,354
- -
Sales/Revenue/Turnover
27.08
30.4
30.58
28.19
24.82
15.46
27.01
25.77
24.11
19.58
17.46
14.21
14.06
13.91
10.73
11.91
- -
Operating Margin (%)
7
13
23
27
51
88
172
238
175
256
284
305
311
302
301
311
- -
Depreciation Expense
266
527
743
821
807
251
954
933
843
1,005
1,137
508
612
582
-54
196
- -
Net Income, GAAP
20.47
26.13
29.27
29.38
27.86
41.81
27.78
32.16
44.82
35.79
29.16
40.19
40.66
37.68
127.3
65.17
- -
Effective Tax Rate (%)
21.54
24.09
21.97
17.99
17.05
5.2
14.67
11.52
8.32
9.2
10.15
4.4
4.79
4.18
-0.41
1.37
- -
Profit Margin (%)
1,626
1,735
1,158
821
3,068
-2,041
-805
693
1,331
1,995
1,691
-1,308
725
-3,308
750
681
-784
Working Capital
- -
- -
- -
- -
2,411
2,659
4,785
5,491
5,731
5,970
6,110
6,309
8,661
4,463
8,470
7,943
5,891
LT Debt
1,660
1,978
2,323
2,516
2,917
3,602
3,196
4,213
4,850
5,594
6,203
5,885
6,142
6,295
5,813
5,991
6,514
Total Equity
28.44
25.79
29.48
24.61
18.25
5.14
11.84
13.45
12.16
11.66
11.33
7.02
6.73
7.65
-2.23
3.13
- -
Return on Invested Capital (%)
29.02
29
32.58
28.27
20.23
3.66
10.92
12.24
10.06
11.03
10.91
4.8
5.94
6.93
-1.9
2.88
- -
Return on Capital (%)
29.03
29
34.56
33.93
29.7
8.07
29.57
25.3
18.61
19.25
19.27
8.41
10.17
9.36
-0.89
3.32
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
975
1,108
1,831
LT Borrowings
8,230
7,815
5,779
LT Finance Leases
104
127
112
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
646
646
646
Market Capitalization
7,139
7,906
5,955

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
5,064
5,296
5,248
Cash, Cash Equivalents & STI
1,812
1,709
1,976
Accounts Receivable, Net
1,144
904
1,025
Inventories
1,933
1,968
1,982
Total Current Liabilities
4,228
4,615
6,032
Payables & Accruals
- -
- -
- -
ST Debt
975
1,108
1,831
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.9%
-0.57%
3.05%
Free Cash Flow
48.92%
2.99%
15.48%
Net Income, GAAP
-31.3%
-122.84%
-465.11%
Sales/Revenue/Turnover
12.14%
5.3%
9.97%
Total Cash Common Dividend
- -
-16.54%
-49.82%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
13,052
2025
- -
- -
14,354
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.08
2025
- -
- -
0.31
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.44
2025
- -
- -
0.22
2026
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Health and Happiness (H&H) International Holdings Limited Health and Happiness (H&H) International Holdings Limited (1112.HK) is an investment holding company principally engaged in the manufacture and sale of pediatric nutrition and baby care, adult nutrition and care, and pet nutrition and care products; its core offerings span infant milk formulas, growing-up milks, and nutritional products for expectant and nursing mothers under the Baby Nutrition and Care (BNC) segment including the Biostime brand; probiotics and nutritional supplements for infants, children, and mothers; vitamins, herbal and mineral supplements, skin care, and sports nutrition under the Adult Nutrition and Care (ANC) segment featuring brands such as Swisse and Aurelia; and pet foods, treats, and supplements under the Pet Nutrition and Care (PNC) segment with brands like Solid Gold Pet, Zesty Paws, and Dodie; other pediatric products include dried baby foods and baby care items under brands like Good Goût. The company, founded in 1999 and formerly known as Biostime International Holdings Limited, maintains its headquarters at One Island East, Taikoo Place in Hong Kong, with a second head office in London and additional operations in Guangzhou, Melbourne, Paris, Singapore, Amsterdam, Bengaluru, Culver City, Bangkok, and Dubai; it serves consumer markets primarily in Mainland China, Australia, New Zealand, North America, and other international regions through premium brands backed by scientific research in a holistic family health approach targeting nutrition, probiotics, and wellness. In recent developments, the group reported a 4.9% revenue increase to RMB7,019.2 million for the first half of 2025 driven by growth across all three segments and higher-margin nutritional supplements, alongside operational efficiency gains that improved the adjusted EBITDA margin to 5.7%; it partnered with Centric Software in March 2025 to implement PLM technology for enhanced global R&D collaboration, product innovation, and digital transformation; formed a new alliance with Greater Good Charities in 2024 to support sustainability initiatives; and continued strategic focus on premiumization, high-margin products, and global expansion following the full rollout of reformulated infant formulas compliant with China's new GB standards in 2024, while pursuing B Corp certification targeted for 2025.

Company News

Company News APIChatGPT

  • defenseworld.net

    Health and Happiness (H&H) International (OTCMKTS:BTSDF) Reaches New 12-Month High – Here’s Why

  • defenseworld.net

    Health and Happiness (H&H) International Holdings Limited (OTCMKTS:BTSDF) Short Interest Update

  • defenseworld.net

    Head to Head Survey: Health and Happiness (H&H) International (OTCMKTS:BTSDF) & Sadot Group (NASDAQ:SDOT)

  • defenseworld.net

    Financial Survey: Health and Happiness (H&H) International (OTCMKTS:BTSDF) versus Energizer (NYSE:ENR)

  • defenseworld.net

    Comparing Health and Happiness (H&H) International (OTCMKTS:BTSDF) and WD-40 (NASDAQ:WDFC)

  • defenseworld.net

    Head to Head Survey: Grove Collaborative (NYSE:GROV) vs. Health and Happiness (H&H) International (OTCMKTS:BTSDF)

  • defenseworld.net

    Comparing Village Farms International (NASDAQ:VFF) and Health and Happiness (H&H) International (OTCMKTS:BTSDF)